Similarly, colchicine, an anti-inflammatory drug that targets the NLRP3 inflammasome/IL-1β-IL-6 axis, has been effective in reducing cardiac events in patients with atherosclerosis in trials like COLCOT (Colchicine Cardiovascular Outcomes Trial) and LoDoCo2 (Low-Dose Colchicine 2 Trial) [17,18,19]. This evidence concerns the gene IL6 and atherosclerosis.